Breadcrumb Navigation:

Home > MS Clinical Care and Research Professionals > Resources to Support Clinical Care > MS Clinical Mgmt > Managing MS > Comprehensive Care > Disease Modification > Indications, Dosing, etc.

Resources to Support Clinical Care

Additional Information

  • Potential Mechanisms and Common Side Effects [Link to continuation of table in CC]
  • Warnings and Safety Management Strategies [Link to continuation of table in CC]
  • Patient Support Programs [Link to continuation of table in CC]
  • Information about Reproductive Issues in MS
  • Visit the Emerging Therapies Collaborative at www.ms-coalition.org/EmergingTherapies for tools created jointly by MS organizations to facilitate doctor-patient communication about emerging therapies.

Need More Information?

Indications, Dosing, etc.

FDA-approved DMTs: Indications, Dosing, Route of Administration, and Pregnancy Rating

 

 

Indications

Dosing

Route of Administration

Pregnancy Rating

Interferon b-1a [Avonex]

Relapsing forms of MS*

CIS

30 mcg weekly

IM

 

 

For all: C

Interferon b-1a    [Rebif]

Relapsing forms of MS*

Study 1

Study 2

44 mcg tiw

SQ

Interferon b-1b

[Betaseron]

Relapsing forms of MS*

CIS

250 mcg                     every other day

SQ

Interferon b-1b [Extavia]

Relapsing forms of MS*

CIS

Formulation identical to Betaseron; no additional studies done

250 mcg                       every other day

SQ

Glatiramer acetate [Copaxone]

Relapsing-remitting MS

CIS

20 mg qd

SQ

B

Fingolimod                 [Gilenya]

Relapsing forms of MS*

Study 1

Study 2

0.5 mg qd

Oral

C

Teriflunomide

[Aubagio]

Relapsing forms of MS*

Study 1

7.0 mg and 14.0 mg; qd

Oral

X

Dimethyl fumerate

[Tecfidera]

Relapsing forms of MS*

Study 1

Study 2

 240 mg bid Oral C

Natalizumab [Tysabri]

Relapsing forms of MS* As monotherapy; generally recommended for those who had an inadequate response to, or could not tolerate, a first-line therapy; no concurrent or prior use of immunosuppressant

Study 1

Study 2

300 mg q 4 wks

IV

C

Mitoxantrone [Novantrone]

SPMS, PRMS, worsening relapsing-remitting MS

12 mg/m2 q 3 mos

Lifetime max: 8-12 doses total (140 mg/m2)

IV

D

*Relapsing forms include relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS), in those patients who continue to have relapses.